Guardant Health (NASDAQ:GH) Director Sells $19,242.08 in Stock

Guardant Health, Inc. (NASDAQ:GH) Director Musa Tariq sold 116 shares of the business’s stock in a transaction dated Friday, October 16th. The shares were sold at an average price of $165.88, for a total transaction of $19,242.08. Following the sale, the director directly owned 11,583 shares of the company’s stock, valued at approximately $1,921,388.04. This represents a 0.99% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Musa Tariq also recently made the following trade(s):

• On Wednesday, September 16th, Musa Tariq sold 116 shares of Guardant Health stock. The stock was sold at an average price of $175.00, for a total transaction of $20,300.00.
• On Monday, August 17th, Musa Tariq sold 116 shares of Guardant Health stock. The stock was sold at an average price of $156.45, for a total transaction of $18,148.20.

Guardant Health Stock Up 2.5%

Shares of NASDAQ GH opened at $166.66 on Thursday. The firm’s 50-day moving average price is $167.73 and its two-hundred day moving average price is $141.01. Guardant Health, Inc. has a 52-week low of $66.59 and a 52-week high of $191.05. The stock has a market capitalization of $22.37 billion, a P/E ratio of -47.75 and a beta of 1.58.

Guardant Health (NASDAQ:GH) last posted its earnings results on Thursday, July 30th. The company reported ($0.42) EPS for the quarter, beating the consensus estimate of ($0.76) by $0.34. The company had revenue of $334.98 million for the quarter, compared to the consensus estimate of $314.23 million. The firm’s revenue for the quarter was up 44.3% compared to the same quarter last year. During the same period last year, the company posted ($0.44) earnings per share. As a group, equities research analysts expect that Guardant Health, Inc. will post -3.02 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts recently commented on GH shares. Morgan Stanley upped their price objective on Guardant Health from $185.00 to $200.00 and gave the stock an “overweight” rating in a research note on Monday, October 12th. Piper Sandler reaffirmed an “overweight” rating on shares of Guardant Health in a research report on Tuesday, September 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Guardant Health in a research note on Thursday, October 15th. Rothschild & Co Redburn assumed coverage on shares of Guardant Health in a report on Tuesday, September 8th. They set a “buy” rating and a $203.00 price target for the company. Finally, Guggenheim boosted their price target on shares of Guardant Health from $190.00 to $200.00 and gave the company a “buy” rating in a report on Thursday, October 1st. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $190.00.

Institutional Trading of Guardant Health

Several large investors have recently added to or reduced their stakes in GH. The Manufacturers Life Insurance Company bought a new stake in Guardant Health during the 2nd quarter valued at $208,592,000. William Blair Investment Management LLC bought a new position in shares of Guardant Health in the second quarter worth $196,737,000. First Light Asset Management LLC grew its stake in shares of Guardant Health by 57.5% in the second quarter. First Light Asset Management LLC now owns 441,586 shares of the company’s stock worth $66,251,000 after purchasing an additional 161,287 shares in the last quarter. Orbimed Advisors LLC bought a new position in shares of Guardant Health in the first quarter worth $40,199,000. Finally, Sei Investments Co. increased its holdings in shares of Guardant Health by 30.2% during the first quarter. Sei Investments Co. now owns 341,013 shares of the company’s stock valued at $31,499,000 after purchasing an additional 79,071 shares during the period. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Guardant Health Company Profile

Guardant Health, Inc (NASDAQ:GH) is a precision oncology company that develops blood-based tests and data solutions designed to help detect cancer, guide treatment decisions and monitor patients over time. Its technologies analyze circulating tumor DNA and other molecular information from blood samples, supporting more accessible and less invasive alternatives to some tissue-based testing approaches.

The company’s products include Guardant360, which helps identify genomic alterations in advanced cancers and may inform targeted treatment selection; Guardant360 Response, designed to assess a patient’s response to therapy; and Guardant Reveal, which is used to detect minimal residual disease and recurrence risk in certain cancers.